CSIMarket
 
Adaptimmune Therapeutics Plc  (NASDAQ: ADAP)
 

Adaptimmune Therapeutics Plc's Customers Performance

ADAP



 
ADAP's Source of Revenues During the corresponding time, Adaptimmune Therapeutics Plc saw a revenue deteriorated by -89.33 % year on year, sequentially revenue grew by 87.74 %. While revenue at the Adaptimmune Therapeutics Plc's corporate clients

List of ADAP Customers




for the same period Adaptimmune Therapeutics Plc revnue deteriorated by -89.33 % year on year, sequentially revenue grew by 87.74 %.

List of ADAP Customers

Adaptimmune Therapeutics Plc's Business Units
Product revenue net    81 % of total Revenue
Development revenue    19 % of total Revenue






Adaptimmune Therapeutics Plc's Comment on Sales, Marketing and Customers
















ADAP's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Adaptimmune Therapeutics Plc 14.50 181.45 -169.76 246
SUBTOTAL 0.00 0.00 0.00 -

Sources: Adaptimmune Therapeutics Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Adaptimmune Therapeutics Plc’s corporate clients.
For your research, we’ve provided 9 tables on Adaptimmune Therapeutics Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.